383 related articles for article (PubMed ID: 29360463)
1. Ceragenin CSA13 Reduces Clostridium difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites.
Wang J; Ghali S; Xu C; Mussatto CC; Ortiz C; Lee EC; Tran DH; Jacobs JP; Lagishetty V; Faull KF; Moller T; Rossetti M; Chen X; Koon HW
Gastroenterology; 2018 May; 154(6):1737-1750. PubMed ID: 29360463
[TBL] [Abstract][Full Text] [Related]
2. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment.
Lv Z; Peng G; Liu W; Xu H; Su J
Antimicrob Agents Chemother; 2015 Jul; 59(7):3726-35. PubMed ID: 25824219
[TBL] [Abstract][Full Text] [Related]
3. Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients.
Fishbein SRS; Hink T; Reske KA; Cass C; Struttmann E; Iqbal ZH; Seiler S; Kwon JH; Burnham CA; Dantas G; Dubberke ER
mSphere; 2021 Jan; 6(1):. PubMed ID: 33441409
[No Abstract] [Full Text] [Related]
4. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice.
Warren CA; van Opstal EJ; Riggins MS; Li Y; Moore JH; Kolling GL; Guerrant RL; Hoffman PS
Antimicrob Agents Chemother; 2013 Feb; 57(2):689-96. PubMed ID: 23147742
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting Growth of Clostridioides difficile by Restoring Valerate, Produced by the Intestinal Microbiota.
McDonald JAK; Mullish BH; Pechlivanis A; Liu Z; Brignardello J; Kao D; Holmes E; Li JV; Clarke TB; Thursz MR; Marchesi JR
Gastroenterology; 2018 Nov; 155(5):1495-1507.e15. PubMed ID: 30025704
[TBL] [Abstract][Full Text] [Related]
6. Efficacy Assessment of the Co-Administration of Vancomycin and Metronidazole in
Zhong S; Yang J; Huang H
J Microbiol Biotechnol; 2024 Apr; 34(4):828-837. PubMed ID: 38668685
[TBL] [Abstract][Full Text] [Related]
7. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W
Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin Treatment Alters Humoral Immunity and Intestinal Microbiota in an Aged Mouse Model of Clostridium difficile Infection.
van Opstal E; Kolling GL; Moore JH; Coquery CM; Wade NS; Loo WM; Bolick DT; Shin JH; Erickson LD; Warren CA
J Infect Dis; 2016 Jul; 214(1):130-9. PubMed ID: 26917573
[TBL] [Abstract][Full Text] [Related]
9. Impact of Oral Fidaxomicin Administration on the Intestinal Microbiota and Susceptibility to Clostridium difficile Colonization in Mice.
Ajami NJ; Cope JL; Wong MC; Petrosino JF; Chesnel L
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463537
[No Abstract] [Full Text] [Related]
10. Clearance of Clostridioides difficile Colonization Is Associated with Antibiotic-Specific Bacterial Changes.
Lesniak NA; Schubert AM; Sinani H; Schloss PD
mSphere; 2021 May; 6(3):. PubMed ID: 33952668
[TBL] [Abstract][Full Text] [Related]
11. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
[TBL] [Abstract][Full Text] [Related]
12. An Integrated Metabolomic and Microbiome Analysis Identified Specific Gut Microbiota Associated with Fecal Cholesterol and Coprostanol in Clostridium difficile Infection.
Antharam VC; McEwen DC; Garrett TJ; Dossey AT; Li EC; Kozlov AN; Mesbah Z; Wang GP
PLoS One; 2016; 11(2):e0148824. PubMed ID: 26871580
[TBL] [Abstract][Full Text] [Related]
13. Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial.
Hota SS; Sales V; Tomlinson G; Salpeter MJ; McGeer A; Coburn B; Guttman DS; Low DE; Poutanen SM
Clin Infect Dis; 2017 Feb; 64(3):265-271. PubMed ID: 28011612
[TBL] [Abstract][Full Text] [Related]
14. Clostridium difficile and inflammatory bowel disease: role in pathogenesis and implications in treatment.
Nitzan O; Elias M; Chazan B; Raz R; Saliba W
World J Gastroenterol; 2013 Nov; 19(43):7577-85. PubMed ID: 24282348
[TBL] [Abstract][Full Text] [Related]
15. Recurrent Clostridium difficile infections: the importance of the intestinal microbiota.
Zanella Terrier MC; Simonet ML; Bichard P; Frossard JL
World J Gastroenterol; 2014 Jun; 20(23):7416-23. PubMed ID: 24966611
[TBL] [Abstract][Full Text] [Related]
16. Fidaxomicin inhibits Clostridium difficile toxin A-mediated enteritis in the mouse ileum.
Koon HW; Ho S; Hing TC; Cheng M; Chen X; Ichikawa Y; Kelly CP; Pothoulakis C
Antimicrob Agents Chemother; 2014 Aug; 58(8):4642-50. PubMed ID: 24890583
[TBL] [Abstract][Full Text] [Related]
17. A review of the economics of treating Clostridium difficile infection.
Mergenhagen KA; Wojciechowski AL; Paladino JA
Pharmacoeconomics; 2014 Jul; 32(7):639-50. PubMed ID: 24807468
[TBL] [Abstract][Full Text] [Related]
18. Defined Nutrient Diets Alter Susceptibility to Clostridium difficile Associated Disease in a Murine Model.
Moore JH; Pinheiro CC; Zaenker EI; Bolick DT; Kolling GL; van Opstal E; Noronha FJ; De Medeiros PH; Rodriguez RS; Lima AA; Guerrant RL; Warren CA
PLoS One; 2015; 10(7):e0131829. PubMed ID: 26181795
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Clostridium difficile infection using SQ641, a capuramycin analogue, increases post-treatment survival and improves clinical measures of disease in a murine model.
Moore JH; van Opstal E; Kolling GL; Shin JH; Bogatcheva E; Nikonenko B; Einck L; Phipps AJ; Guerrant RL; Protopopova M; Warren CA
J Antimicrob Chemother; 2016 May; 71(5):1300-6. PubMed ID: 26832756
[TBL] [Abstract][Full Text] [Related]
20. Fecal pharmacokinetics/pharmacodynamics characteristics of fidaxomicin and vancomycin against Clostridioides difficile infection elucidated by in vivo feces-based infectious evaluation models.
Tashiro S; Taguchi K; Enoki Y; Matsumoto K
Clin Microbiol Infect; 2023 May; 29(5):616-622. PubMed ID: 36574949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
